As part of our research on compulsory licensing we have now added a case study on efavirenz – the antiretroviral that Brazil needed for its public funded HIV treatment program. Brazil was forced to do so because of failure of negotiation for a voluntary license by the patent holder, Merck. This case is the first addition to a new section entitled: Case Studies in Global Health
Recent Posts
- New publication from the ATP consortium
- New Publication on Socially Responsible Licensing Initiatives in South Africa
- New publication on R&D for Neglected Diseases from the University of Neuchâtel
- Compulsory licensing of an antiretroviral in Brazil
- St. George’s Global Health Forum, and local UAEM Chapter
Recent Comments